The company provides comprehensive logistics and freight forwarding services, managing the international and domestic movement of goods via air, sea, and road for commercial clients.
The company operates in a highly fragmented and commoditized freight forwarding market where profitability is low and returns on capital are negligible. While they possess industry certifications, the lack of durable pricing power is evidenced by an average ROE near zero and a significant decline in net profit margins despite revenue growth.
Capital has been primarily directed toward a major merger and the acquisition of a subsidiary, yet these actions have not yet translated into meaningful returns for shareholders, as evidenced by the very low ROCE of 2.6%.
The company collapsed under the weight of its own debt as the interest coverage ratio of 0.25 proved fatal. Despite massive revenue growth, the business remained a 'profitless prosperity' machine where capital was incinerated on low-return acquisitions and related-party transactions. The inability to generate cash from operations, combined with regulatory penalties for unauthorized managerial pay, eventually led to a liquidity crisis that wiped out equity holders while promoters continued to extract value through offices of profit.
RichFakir rates East West Freight Carriers Ltd's business quality as poor — 7/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, East West Freight Carriers Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on East West Freight Carriers Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of East West Freight Carriers Ltd's fair value is about ₹1 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →